AIxCrypto Holdings, BitMart launch co‑branded virtual prepaid card to bridge Web3 payments
- AIxCrypto Holdings partners with BitMart to launch a co‑branded virtual prepaid card for everyday online and wallet payments.
- AIxCrypto supplies community reach, brand participation and marketing; BitMart manages issuance, onboarding, customer support and compliance.
- AIxCrypto calls the card part of its AIxC/BesTrade roadmap, but warns outcomes depend on regulatory, licensing and timing risks.
AIxCrypto, BitMart roll out co‑branded virtual prepaid card to bridge Web3 and everyday payments
AIxCrypto Holdings is partnering with crypto exchange BitMart to launch a co‑branded virtual prepaid card that aims to make blockchain‑linked payments usable for routine online and digital‑wallet transactions. The card is designed for everyday digital payments and integrates with major wallet networks, giving eligible members of AIxCrypto’s global community a route to spend in familiar merchant environments subject to regional availability and terms.
The agreement makes a clear division of labor: AIxCrypto contributes community reach, brand participation and marketing channels, while BitMart acts as the exclusive operator and is solely responsible for card issuance, user onboarding, customer support and the entire payments infrastructure. BitMart also bears responsibility for regulatory compliance, licensing and adherence to payment‑network rules, reflecting a deliberate separation between AIxCrypto’s ecosystem engagement role and BitMart’s regulated financial operations.
AIxCrypto frames the initiative as part of a broader strategy to deliver practical utility and scalable, compliance‑minded products that bridge Web2 and Web3. The company highlights its BesTrade DeAI Agent and wider AIxC ecosystem as roadmap components that pair AI capabilities with blockchain features, while noting that final product terms — rollout timing, eligibility, transaction limits, fees and supported currencies — will be disclosed by BitMart in line with regional laws, licensing timelines and consumer protection standards.
Forward‑looking statements and risk caveats
The announcement contains customary forward‑looking statements under the Private Securities Litigation Reform Act, and AIxCrypto warns that expectations about future actions, results and timelines are subject to risks and uncertainties, including regulatory developments and the pace of licensing for payment products in different jurisdictions.
Industry context: payments as the bridge to mainstream crypto use
The tie‑up follows a broader industry trend in which crypto firms partner with licensed payment operators to convert digital assets into spendable balances and to offer consumers familiar card rails. Market observers say such partnerships aim to provide real‑world utility for crypto ecosystems while limiting regulatory exposure for project founders by placing issuance and compliance with established financial firms.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…